S
Shannon L. Maude
Researcher at Children's Hospital of Philadelphia
Publications - 133
Citations - 16914
Shannon L. Maude is an academic researcher from Children's Hospital of Philadelphia. The author has contributed to research in topics: Chimeric antigen receptor & Cytokine release syndrome. The author has an hindex of 40, co-authored 117 publications receiving 12307 citations. Previous affiliations of Shannon L. Maude include University of Pennsylvania.
Papers
More filters
Journal ArticleDOI
Chimeric antigen receptor T cells for sustained remissions in leukemia.
Shannon L. Maude,Noelle Frey,Pamela A. Shaw,Richard Aplenc,David M. Barrett,Nancy Bunin,Anne Chew,Vanessa E. Gonzalez,Zhaohui Zheng,Simon F. Lacey,Yolanda D. Mahnke,J. Joseph Melenhorst,Susan R. Rheingold,Angela Shen,David T. Teachey,Bruce L. Levine,Carl H. June,David L. Porter,Stephan A. Grupp +18 more
TL;DR: Chimeric antigen receptor-modified T-cell therapy against CD19 was effective in treating relapsed and refractory ALL and was associated with a high remission rate, even among patients for whom stem-cell transplantation had failed, and durable remissions up to 24 months were observed.
Journal ArticleDOI
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
Shannon L. Maude,Theodore W. Laetsch,Jochen Buechner,S. Rives,Michael Boyer,Henrique Bittencourt,Peter Bader,Michael R. Verneris,Heather E. Stefanski,G.D. Myers,Muna Qayed,B. De Moerloose,Hidefumi Hiramatsu,Krysta Schlis,Kara L. Davis,Paul L. Martin,Eneida R. Nemecek,Gregory A. Yanik,Christina Peters,André Baruchel,Nicolas Boissel,Francoise Mechinaud,Adriana Balduzzi,Joerg Krueger,Carl H. June,Bruce L. Levine,Patricia A. Wood,Tanya Taran,Mimi Leung,Karen Thudium Mueller,Yiyun Zhang,Kapildeb Sen,David Lebwohl,Michael A. Pulsipher,Stephan A. Grupp +34 more
TL;DR: In this global study of CAR T‐cell therapy, a single infusion of tisagenlecleucel provided durable remission with long‐term persistence in pediatric and young adult patients with relapsed or refractory B‐cell ALL, with transient high‐grade toxic effects.
Journal ArticleDOI
Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy
Elena Sotillo,David M. Barrett,Kathryn L. Black,Asen Bagashev,Derek A. Oldridge,Glendon S. Wu,Robyn T. Sussman,Claudia Lanauze,Marco Ruella,Matthew R. Gazzara,Nicole M. Martinez,Colleen T. Harrington,Elaine Y. Chung,Jessica Perazzelli,Ted J. Hofmann,Shannon L. Maude,Pichai Raman,Alejandro Barrera,Saar Gill,Simon F. Lacey,J. Joseph Melenhorst,David Allman,Elad Jacoby,Terry J. Fry,Crystal L. Mackall,Yoseph Barash,Kristen W. Lynch,John M. Maris,Stephan A. Grupp,Andrei Thomas-Tikhonenko +29 more
TL;DR: It is discovered that the underlying mechanism is the selection for preexisting alternatively spliced CD19 isoforms with the compromised CART-19 epitope, which suggests a possibility of targeting alternative CD19 ectodomains, which could improve survival of patients with B-cell neoplasms.
Journal ArticleDOI
Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T cell Therapy for Acute Lymphoblastic Leukemia
David T. Teachey,David T. Teachey,Simon F. Lacey,Pamela A. Shaw,J. Joseph Melenhorst,Shannon L. Maude,Noelle V. Frey,Edward Pequignot,Vanessa E. Gonzalez,Fang Chen,Jeffrey Finklestein,David M. Barrett,Scott L. Weiss,Julie C. Fitzgerald,Robert A. Berg,Richard Aplenc,Colleen Callahan,Susan R. Rheingold,Zhaohui Zheng,Stefan Rose-John,Jason C. White,Farzana Nazimuddin,Gerald Wertheim,Bruce L. Levine,Carl H. June,David L. Porter,Stephan A. Grupp +26 more
TL;DR: The first models that can accurately predict which patients are likely to develop severe CRS before they become critically ill are developed, which improves understanding of CRS biology and may guide future cytokine-directed therapy.
Journal ArticleDOI
Managing cytokine release syndrome associated with novel T cell-engaging therapies.
TL;DR: One approach has developed targets IL-6, a prominent cytokine in CRS, using the IL- 6R antagonist tocilizumab, which has the potential to provide superior toxicity control without compromising efficacy.